Download Image
    
Share
  
Post
Empagliflozin for COVID-19
1 study with >4,000 patients
Hospital Icon Control Serious Outcome Risk
Hospital Icon Empagliflozin
No significant improvements are seen in meta analysis to date.
COVID-19 Empagliflozin studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies 4% Mortality 4% RCTs 4% Late 4% Favorsempagliflozin Favorscontrol
Sep 2
 Horby et al., medRxiv, doi:10.1101/2025.08.29.25334732 Long-term follow-up of treatment comparisons in RECOVERY: a randomised, open-label, platform trial for patients hospitalised with COVID-19
6-month followup of RECOVERY patients. Results are reported within the respective trials for each treatment.
Dec 31
2023
 Horby et al., The Lancet Diabetes & Endocrinology, doi:10.1016/S2213-8587(23)00253-X Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
4% lower mortality (p=0.59), 3% lower ventilation (p=0.77), and 3% higher hospital discharge (p=0.44). RCT 4,271 hospitalized COVID-19 patients showing no significant difference in outcomes with empagliflozin treatment. 6-month results are from [Horby]